Skip to main content

Advertisement

SpringerLink
Log in

Outlook for the next 5 years in drug innovation

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Compounds in clinical development by therapeutic area.
Figure 2: Innovative pipeline composition by therapeutic area.
Figure 3: Historic and forecasted number of launches.

References

  1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–215 (2010).

    CAS  Google Scholar 

  2. David, E., Tramontin, T. & Zemmel, R. Pharmaceutical R&D: the road to positive returns. Nature Rev. Drug Discov. 8, 609–610 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Roy Berggren is at McKinsey & Company, 55 East 52nd Street, 16th Floor, New York, 10022, USA.,

    Roy Berggren

  2. Martin Møller is at McKinsey & Company, Ved Stranden 14, DK-1061 Copenhagen K, Denmark.,

    Martin Møller

  3. Rachel Moss is at McKinsey & Company, No. 1 Jermyn Street, London SW1Y 4UH, UK.,

    Rachel Moss

  4. Pawel Poda and Katarzyna Smietana are at McKinsey & Company, Plac Grunwaldzki 23, Wroclaw 50-365, Poland.,

    Pawel Poda & Katarzyna Smietana

Authors
  1. Roy Berggren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel Moss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pawel Poda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katarzyna Smietana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Møller.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information Box S1

Data sources and analysis methodology (PDF 128 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berggren, R., Møller, M., Moss, R. et al. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov 11, 435–436 (2012). https://doi.org/10.1038/nrd3744

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3744

  • Springer Nature Limited

This article is cited by

Search

Navigation